Onconetix extends Realbotix deal deadline to March 31, 2027

• Onconetix amended its February 11, 2026, share exchange agreement involving Realbotix on November 4, 2026.
• Simulacra will own 95% of the buyer's fully diluted shares if net cash is below $12.5 million and closing proceeds.
• Net cash includes cash, cash equivalents, and outstanding principal and accrued interest under the September 11, 2026, Grid Promissory Note.
• The transaction's end date was extended to March 31, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-116512), on November 06, 2026, and is solely responsible for the information contained therein.